Release Date: December 6, 2025
Expiration Date: January 30, 2026
Activity Overview
Chronic graft-versus-host disease (GVHD) is a major late complication of allogeneic hematopoietic cell transplantation, with limited responses to corticosteroids and significant unmet need in the steroid-refractory setting. This live, hybrid Medical Crossfire® symposium brings together leading experts to review best practices for prevention, diagnosis, and management of chronic GVHD, with a key focus on the optimal sequencing of therapy along the treatment continuum. Discussions highlight patient selection, toxicity management, and the role of multidisciplinary collaboration, while a forward-looking session explores combination strategies, emerging agents, and key updates from this year’s American Society of Hematology meeting.
This educational activity is an archive of the live presentation held on December 5, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, hematologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of GVHD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the mechanism of action for current and emerging therapies being evaluated for the prophylaxis and treatment of GVHD
- Analyze efficacy and safety from recent and ongoing clinical trials evaluating targeted therapies for the treatment of GVHD
- Integrate current evidence and treatment guidelines to personalize care for GVHD
- Utilize strategies to readily identify and optimally manage treatment-related toxicities in patients with GVHD
Corey Cutler, MD, MPH, FRCP(C)
Director of Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA
Amin M. Alousi, MD
Professor of Medicine
Inpatient Medical Director
Director, Multidiscipline GVHD Clinic and Research Program
Department of Stem Cell Transplantation and Cellular Therapy
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Mehdi Hamadani, MD
Professor of Medicine
Section Chief of Hematologic Malignancies
Scientific Director, CIBMTR
Division of Hematology & Oncology
Co-Associate Director of Clinical Research
Cancer Center Scholar Endowed Chair
Froedtert & MCW Clinical Cancer Center
Medical College of Wisconsin
Milwaukee, WI
Anna Sureda, MD, PhD
Head of the Hematology Department and Hematopoietic Stem Cell
Transplant Programme
Institut Català d'Oncologia
Hospital Duran i Reynals
Gran Via de l'Hospitalet
Barcelona, Spain
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
